Janux Therapeutics, Inc.JANXEarnings & Financial Report
Janux Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing novel T cell engager immunotherapies for treating solid tumors and hematological malignancies. It primarily operates in the U.S. biopharmaceutical market, focusing on the oncology segment to address unmet medical needs for patients with hard-to-treat cancers.
JANX Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-42.4M
Net Profit
$-31.9M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.51
Janux Therapeutics, Inc. Q4 FY2025 Financial Summary
Janux Therapeutics, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of $-31.9M (down 58.0% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-31.9M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Janux Therapeutics, Inc. Annual Revenue by Year
Janux Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.0M).
Janux Therapeutics, Inc. Quarterly Revenue & Net Profit History
Janux Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-31.9M | N/A |
| Q3 FY2025 | $10.0M | +2177.9% | $-24.3M | -243.1% |
| Q2 FY2025 | $0 | — | $-33.9M | N/A |
| Q1 FY2025 | $0 | — | $-23.5M | N/A |
| Q4 FY2024 | $0 | — | $-20.2M | N/A |
| Q3 FY2024 | $439.0K | -82.6% | $-28.1M | -6391.6% |
| Q2 FY2024 | $8.9M | +741.7% | $-6.0M | -67.0% |
| Q1 FY2024 | $1.3M | -38.9% | $-14.8M | -1178.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $8.9M | $439000 | $0 | $0 | $0 | $10.0M | $0 |
| YoY Growth | -38.9% | 741.7% | -82.6% | N/A | N/A | N/A | 2177.9% | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $689.0M | $691.4M | $695.0M | $1.06B | $1.05B | $1.03B | $1.02B | $1.00B |
| Liabilities | $33.2M | $33.7M | $38.9M | $38.7M | $38.3M | $41.7M | $48.2M | $44.7M |
| Equity | $655.8M | $657.7M | $656.1M | $1.02B | $1.01B | $990.5M | $976.6M | $956.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.8M | $-10.0M | $-2.2M | $-16.7M | $-17.0M | $-23.8M | $-12.9M | $-28.5M |